AIM: To compare bleeding within 48 h in patients undergoing percutaneous endoscopic gastrostomy (PEG) with or without clopidogrel. METHODS: After institutional review board approval, a retrospective study involving a single center was conducted on adult patients having PEG (1/08-1/14). Patients were divided into two groups: Clopidogrel group consisting of those patients taking clopidogrel within 5 d of PEG and the non-clopidogrel group including those patients not taking clopidogrel within 5 d of the PEG. RESULTS: Three hundred and nineteen PEG patients were found. One hundred and sixty-eight males and 151 females with mean body mass index 28.47 ± 9.75 kg/m(2) and mean age 65.03 ± 16.11 years were identified. Thirty-three patients were on clopidogrel prior to PEG with 286 patients not on clopidogrel. No patients in either group developed hematochezia, melena, or hematemesis within 48 h of percutaneous endoscopic gastrostomy (PEG). No statistical differences were observed between the two groups with 48 h for hemoglobin decrease of > 2 g/dL (2 vs 5 patients; P = 0.16), blood transfusions (2 vs 7 patients; P = 0.24), and repeat endoscopy for possible gastrointestinal bleeding (no patients in either group). CONCLUSION: Based on the results, no significant post-procedure bleeding was observed in patients undergoing PEG with recent use of clopidogrel.
AIM: To compare bleeding within 48 h in patients undergoing percutaneous endoscopic gastrostomy (PEG) with or without clopidogrel. METHODS: After institutional review board approval, a retrospective study involving a single center was conducted on adult patients having PEG (1/08-1/14). Patients were divided into two groups: Clopidogrel group consisting of those patients taking clopidogrel within 5 d of PEG and the non-clopidogrel group including those patients not taking clopidogrel within 5 d of the PEG. RESULTS: Three hundred and nineteen PEGpatients were found. One hundred and sixty-eight males and 151 females with mean body mass index 28.47 ± 9.75 kg/m(2) and mean age 65.03 ± 16.11 years were identified. Thirty-three patients were on clopidogrel prior to PEG with 286 patients not on clopidogrel. No patients in either group developed hematochezia, melena, or hematemesis within 48 h of percutaneous endoscopic gastrostomy (PEG). No statistical differences were observed between the two groups with 48 h for hemoglobin decrease of > 2 g/dL (2 vs 5 patients; P = 0.16), blood transfusions (2 vs 7 patients; P = 0.24), and repeat endoscopy for possible gastrointestinal bleeding (no patients in either group). CONCLUSION: Based on the results, no significant post-procedure bleeding was observed in patients undergoing PEG with recent use of clopidogrel.
Authors: James A DiSario; William N Baskin; Russel D Brown; Mark H DeLegge; John C Fang; Gregory G Ginsberg; Stephen A McClave Journal: Gastrointest Endosc Date: 2002-06 Impact factor: 9.427
Authors: Michelle A Anderson; Tamir Ben-Menachem; S Ian Gan; Vasundhara Appalaneni; Subhas Banerjee; Brooks D Cash; Laurel Fisher; M Edwyn Harrison; Robert D Fanelli; Norio Fukami; Steven O Ikenberry; Rajeev Jain; Khalid Khan; Mary Lee Krinsky; David R Lichtenstein; John T Maple; Bo Shen; Laura Strohmeyer; Todd Baron; Jason A Dominitz Journal: Gastrointest Endosc Date: 2009-11-03 Impact factor: 9.427
Authors: James A Richter; James T Patrie; Robert P Richter; Zachary H Henry; George H Pop; Kara A Regan; David A Peura; Robert G Sawyer; Patrick G Northup; Andrew Y Wang Journal: Gastrointest Endosc Date: 2011-07 Impact factor: 9.427
Authors: Sun-Young Lee; Shou-jiang Tang; Don C Rockey; Douglas Weinstein; Luis Lara; Jayaprakash Sreenarasimhaiah; Kyoo Wan Choi Journal: Gastrointest Endosc Date: 2008-04-02 Impact factor: 9.427